Microbix Biosystems Inc T.MBX

Alternate Symbol(s): MBXBF

Healthcare Biotechnology

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

TSX:MBX - Post by User

Microbix Biosystems Inc > MBX: KRC Insights Equity Research

<< Previous

Bullboard Posts

Next >>

Comment by wizzdumbon Jun 06, 2024 10:44am

130 Views

Post# 36075203

RE:MBX: KRC Insights Equity Research

Very conservative estimate, not even including Kinlytic which is basically a lock and only dependent on timing, and still more than double the current share price. Include Kinlytic and add another buck at minimum. What a steal.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market